drugset / Trial / NCT05461209
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).
Timeline
- Start
- 2022-10-20
- Primary completion
- 2022-11-15
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Belantamab mafodotin | Monoclonal antibody | — | Intravenous |
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |